Citations

Clear

941 citation(s) found for "Tefferi, A".

Kit: Molecule of Interest for the Diagnosis and Treatment of Mastocytosis and other Neoplastic Disorders
Patnaik, Mrinal M. , Tefferi, Ayalew , Pardanani, Animesh

Mayo Clinic

Current Cancer Drug Targets | July 29, 2007 | Volume: 7 | Issue: 5 | Pages: 492-503

10.2174/156800907781386614 | PMID 17691909 Get It

Genomics Basics: DNA Structure, Gene Expression, Cloning, Genetic Mapping, and Molecular Tests
Tefferi, Ayalew

Mayo Clinic

Seminars in Cardiothoracic and Vascular Anesthesia | June 21, 2007 | Volume: 10 | Issue: 4 | Pages: 282-290

10.1177/1089253206294343 | PMID 17200086 Get It

Genomics is the study of the structure and function of the human genome including genes and their surrounding DNA sequences. The over 3 billion base pairs of the human genome have now been sequenced and approximately 25 000 genes acknowledged. However, only 1% of the entire genome has been assigned to protein coding and decades more work is anticipated to define the functional relevance of noncoding DNA as well as the basis and consequences of sequence variations among individuals. For medical scientists, the focus remains on discovering both disease-causing and disease-susceptibility genes. For pharmaceutical companies, the opportunity to develop molecularly targeted therapy is not going unnoticed. For the practicing physician, the prospect of genomic medicine that incorporates molecular diagnosis and pathogenesis-targeted therapy requires basic understanding of terminology and concepts in molecular biology and the corresponding laboratory tests.
Extending Jak2V617F and MplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes
Pardanani, Animesh , Finke, Christy M. , Ketterling, Rhett P. , Gilliland, Dwight Gary, Tefferi, Ayalew , Lasho, Terra L. , Mesa, Ruben A. , Hogan, William J. , Ketterling, Rhett P

Mayo Clinic

Stem Cells | June 1, 2007 | Volume: 25 | Issue: 9 | Pages: 2358-2362

10.1634/stemcells.2007-0175 | PMID 17540852 Get It

Abstract JAK2V617F and MPLW515L/K are myeloproliferative disorder (MPD)-associated mutations. We genotyped 552 individual hematopoietic colonies obtained by CD34+ cell culture from 16 affected patients (13 JAK2V617F and 3 MPLW515L/K) to determine (a) the proportion of colonies harboring a particular mutation in the presence or absence of cytokines, (b) the lineage distribution of endogenous colonies for each mutation, and (c) the differences (if any) in the pattern of mutation among the various MPDs, as established by genotyping of individual colonies. Genotyping analysis revealed cohabitation of mutation-negative and mutation-positive endogenous colonies in polycythemia vera as well as other MPDs. Culture of progenitor cells harboring MPLW515L/K yielded virtually no endogenous erythroid colonies in contrast to JAK2V617F-harboring progenitor cells. The mutation pattern (i.e., relative distribution of homozygous, heterozygous, or wild-type colonies) was not a distinguishing feature among the MPDs, and MPLW515 mutations were detected in B and/or T lymphocytes in all three patients tested. These observations suggest that clonal myelopoiesis antedates acquisition of JAK2V617F or MPLW515L/K mutations and that the latter is acquired in a lympho-myeloid progenitor cell. Disclosure of potential conflicts of interest is found at the end of this article.
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
Tefferi, Ayalew , Thiele, Jüergen, Orazi, Attilio , Kvasnicka, Hans Michael , Barbui, Tiziano , Hanson, Curtis A. , Verstovšek, Srđan , Birgegård, Gunnar , Reilly, John T., Gisslinger, Heinz , Cervantes, Francisco , Gilliland, D. Gary, Bloomfield, Clara D. , Vardiman, James W., Barosi, Giovanni , Mesa, Ruben A. , Vannucchi, Alessandro M. , Finazzi, Guido , Hoffman, Ronald , Verstovsek, Srdan , Orazi, Attilio

Mayo Clinic

Blood | May 8, 2007 | Volume: 110 | Issue: 4 | Pages: 1092-1097

10.1182/blood-2007-04-083501 | PMID 17488875 Get It

Abstract The Janus kinase 2 mutation, JAK2617V>F, is myeloid neoplasm-specific; its presence excludes secondary polycythemia, thrombocytosis, or bone marrow fibrosis from other causes. Furthermore, JAK2617V>F or a JAK2 exon 12 mutation is present in virtually all patients with polycythemia vera (PV), whereas JAK2617V>F also occurs in approximately half of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Therefore, JAK2 mutation screening holds the promise of a decisive diagnostic test in PV while being complementary to histology for the diagnosis of ET and PMF; the combination of molecular testing and histologic review should also facilitate diagnosis of ET associated with borderline thrombocytosis. Accordingly, revision of the current World Health Organization (WHO) diagnostic criteria for PV, ET, and PMF is warranted; JAK2 mutation analysis should be listed as a major criterion for PV diagnosis, and the platelet count threshold for ET diagnosis can be lowered from 600 to 450 × 109/L. The current document was prepared by an international expert panel of pathologists and clinical investigators in myeloproliferative disorders; it was subsequently presented to members of the Clinical Advisory Committee for the revision of the WHO Classification of Myeloid Neoplasms, who endorsed the document and recommended its adoption by the WHO.
The granulocyte connection in MPD-associated thrombosis
Tefferi, Ayalew

Mayo Clinic

Blood | March 6, 2007 | Volume: 109 | Issue: 6 | Pages: 2270-2271

10.1182/blood-2007-01-064550 Get It

Experimental therapy in myelofibrosis with myeloid metaplasia
Verstovšek, Srđan , Kantarjian, Hagop M. , Tefferi, Ayalew , Quintás‐Cardama, Alfonso , Verstovsek, Srdan , Kantarjian, Hagop

Mayo Clinic

Expert Opinion on Investigational Drugs | November 16, 2006 | Volume: 15 | Issue: 12 | Pages: 1555-1563

10.1517/13543784.15.12.1555 | PMID 17107281 Get It

Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR / ABL fusion to ass
Landstrom, Andrew P. , Ketterling, Rhett P. , Knudson, Ryan A., Tefferi, Ayalew , Landstrom, Andrew P , Ketterling, Rhett P

Mayo Clinic

Leukemia & Lymphoma | October 26, 2006 | Volume: 47 | Issue: 10 | Pages: 2055-2061

10.1080/10428190600783551 | PMID 17071476 Get It

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
Kantarjian, Hagop M. , Akin, Cem , Manshouri, Taghi , Lamb, Peter , Cortes, Jörge E. , Tefferi, Ayalew , Verstovšek, Srđan , Pan, Jingxuan , Quintás‐Cardama, Alfonso , Giles, Francis Joseph , Cortes, Jorge , Verstovsek, Srdan , Akin, Cem , Kantarjian, Hagop

Mayo Clinic

Blood | August 16, 2006 | Volume: 109 | Issue: 1 | Pages: 315-322

10.1182/blood-2006-04-013805 | PMID 16912224 Get It

Abstract Gain-of-function mutations of the receptor tyrosine kinase KIT play a key role in the pathogenesis of systemic mastocytosis (SM), gastrointestinal stromal tumors (GISTs), and some cases of acute myeloid leukemia (AML). Whereas KIT juxtamembrane domain mutations seen in most patients with GIST are highly sensitive to imatinib, the kinase activation loop mutant D816V, frequently encountered in SM, hampers the binding ability of imatinib. We investigated the inhibitory activity of the novel tyrosine kinase inhibitor EXEL-0862 against 2 subclones of human mast cell line-1 (HMC-1)—HMC-1.1, harboring the juxtamembrane domain mutation V560G, and HMC-1.2, carrying V560G and the activation loop mutation D816V, found in more than 80% of patients with SM. EXEL-0862 inhibited the phosphorylation of KIT in a dose-dependent manner and decreased cell proliferation in both mast cell lines with higher activity against HMC-1.2 cells. The phosphorylation of KIT-dependent signal transducer and activator of transcription-3 (STAT3) and STAT5 was abrogated upon exposure to nanomolar concentrations of EXEL-0862. In addition, EXEL-0862 induced a time- and dose-dependent proapoptotic effect in both mast cell lines and caused a significant reduction in mast-cell content in bone marrow samples from patients with SM harboring D816V and from those without the D816V mutation. We conclude that EXEL-0862 is active against KIT activation loop mutants and is a promising candidate for the treatment of patients with SM and other KIT-driven malignancies harboring active site mutations.
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, Animesh , Levine, Ross L. , Pikman, Yana , Wadleigh, Martha , Steensma, David P. , Elliott, Michelle A. , Wolanskyj, Alexandra P. , McClure, Rebecca F., Litzow, Mark R. , Gilliland, D. Gary , Tefferi, Ayalew , Lasho, Terra L. , Mesa, Ruben A. , Hogan, William J. , Wolanskyj-Spinner, Alexandra P , Steensma, David P

Mayo Clinic

Blood | July 25, 2006 | Volume: 108 | Issue: 10 | Pages: 3472-3476

10.1182/blood-2006-04-018879 | PMID 16868251 Get It

Abstract Recently, a gain-of-function MPL mutation, MPLW515L, was described in patients with JAK2V617F-negative myelofibrosis with myeloid metaplasia (MMM). To gain more information on mutational frequency, disease specificity, and clinical correlates, genomic DNA from 1182 patients with myeloproliferative and other myeloid disorders and 64 healthy controls was screened for MPL515 mutations, regardless of JAK2V617F mutational status: 290 with MMM, 242 with polycythemia vera, 318 with essential thrombocythemia (ET), 88 with myelodysplastic syndrome, 118 with chronic myelomonocytic leukemia, and 126 with acute myeloid leukemia (AML). MPL515 mutations, either MPLW515L (n = 17) or a previously undescribed MPLW515K (n = 5), were detected in 20 patients. The diagnosis of patients with mutant MPL alleles at the time of molecular testing was de novo MMM in 12 patients, ET in 4, post-ET MMM in 1, and MMM in blast crisis in 3. Six patients carried the MPLW515L and JAK2V617F alleles concurrently. We conclude that MPLW515L or MPLW515K mutations are present in patients with MMM or ET at a frequency of approximately 5% and 1%, respectively, but are not observed in patients with polycythemia vera (PV) or other myeloid disorders. Furthermore, MPL mutations may occur concurrently with the JAK2V617F mutation, suggesting that these alleles may have functional complementation in myeloproliferative disease.
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Tefferi, Ayalew , Cortes, Jörge E. , Verstovšek, Srđan , Thomas, Deborah A. , Litzow, Mark R. , Allred, Jacob B., Byrne, Catriona , Zeldis, Jerome B. , Ketterling, Rhett P. , McClure, Rebecca F., Kantarjian, Hagop M. , Mesa, Ruben A. , Lasho, Terra L. , Hogan, William J. , Jones, Dan M. , Giles, Francis Joseph , Cortes, Jorge , Verstovsek, Srdan , Ketterling, Rhett P , Kantarjian, Hagop

Mayo Clinic

Blood | April 12, 2006 | Volume: 108 | Issue: 4 | Pages: 1158-1164

10.1182/blood-2006-02-004572 | PMID 16609064 Get It

AbstractWe present results of 2 similarly designed but separate phase 2 studies involving single-agent lenalidomide (CC-5013, Revlimid) in a total of 68 patients with symptomatic myelofibrosis with myeloid metaplasia (MMM). Protocol treatment consisted of oral lenalidomide at 10 mg/d (5 mg/d if baseline platelet count < 100 × 109/L) for 3 to 4 months with a plan to continue treatment for either 3 or 24 additional months, in case of response. Overall response rates were 22% for anemia, 33% for splenomegaly, and 50% for thrombocytopenia. Response in anemia was deemed impressive in 8 patients whose hemoglobin level normalized from a baseline of either transfusion dependency or hemoglobin level lower than 100 g/L. Additional treatment effects in these patients included resolution of leukoerythroblastosis (4 patients), a decrease in medullary fibrosis and angiogenesis (2 patients), and del(5)(q13q33) cytogenetic remission accompanied by a reduction in JAK2V617F mutation burden (1 patient). Grade 3 or 4 adverse events included neutropenia (31%) and thrombocytopenia (19%). We conclude that lenalidomide engenders an intriguing treatment activity in a subset of patients with MMM that includes an unprecedented effect on peripheral blood and bone marrow abnormalities.